Rystiggo (rozanolixizumab-noli)

Rystiggo (rozanolixizumab-noli) is covered for adults (≥18) with generalized myasthenia gravis who are AChR- or MuSK‑antibody positive and is not authorized for antibody‑negative patients or those under 18. Coverage requires MGFA class II–IV, MG‑ADL ≥3 for non‑ocular symptoms, prior/current pyridostigmine unless failed/contraindicated/intolerant, neurologist prescribing/consultation, weight‑based SC dosing once weekly for 6 weeks (420–840 mg by weight), initial approval for 6 months (12‑month renewals), documentation of benefit for re‑authorization, and a minimum 63‑day interval before subsequent cycles.

"Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody p..."

Sign up to see full coverage criteria, indications, and limitations.